Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 5/20 | 0.59 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 11/20 | 0.46 |
| ▸ | BRD2 | P25440 | 6/20 | 0.46 |
| ▸ | BRD3 | Q15059 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18359658 | 0.91 | ERN1 (0.55) | ERN1NR3C1BRD4BRD2BRD3 | |
| SCHEMBL18359657 | 0.83 | KDM4E (0.57) | ERN1NR3C1ALDH1A1KDM4EBRD4 | |
| SCHEMBL8326046 | 0.79 | ERN1 (0.72) | ERN1BRD4BRD2BRD3 | |
| SCHEMBL14712715 | 0.79 | BRD4 (0.52) | ERN1NR3C1BRD4BRD2BRD3 | |
| SCHEMBL27336188 | 0.78 | ALDH1A1 (0.62) | ERN1ALDH1A1KDM4ETSHRTDP1 | |
| SCHEMBL6040622 | 0.76 | ABCG2 (0.55) | ALDH1A1TDP1 | |
| SCHEMBL6040618 | 0.76 | ABCG2 (0.55) | ALDH1A1TDP1 | |
| SCHEMBL18949744 | 0.75 | NR3C1 (0.47) | ERN1NR3C1BRD4BRD2BRD3 | |
| SCHEMBL8870304 | 0.74 | ALDH1A1 (0.49) | ERN1ALDH1A1KDM4ETSHRTDP1 | |
| SCHEMBL12767020 | 0.74 | ERN1 (1.00) | ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060189549-A1 | Chalcone derivatives and their use to treat diseases | NI LIMING | 2006-08-24 | — | — | US | disclosed |
| US-7094801-B2 | Chalcone derivatives and their use to treat diseases | ATHEROGENICS, INC. (US) | 2006-08-22 | — | — | US | disclosed |
| EP-1465854-A4 | CHALCONE DERIVATIVES AND THEIR USE TO TREAT DISEASES | ATHEROGENICS INC (US) | 2005-06-08 | — | — | EP | disclosed |
| CN-1596240-A | Chalcone derivatives and their use for the treatment of diseases | ATHEROGENICS INC (US) | 2005-03-16 | — | — | CN | disclosed |
| EP-1465854-A2 | CHALCONE DERIVATIVES AND THEIR USE TO TREAT DISEASES | Atherogenics, Inc. (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20040048858-A1 | Chalcone derivatives and their use to treat diseases | CRABTREE ACQUISITION CO, LLC | 2004-03-11 | — | — | US | disclosed |
| WO-2003053368-A2 | CHALCONE DERIVATIVES AND THEIR USE TO TREAT DISEASES | ATHEROGENICS, INC. (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189549-A1 | Chalcone derivatives and their use to treat diseases | CYP46A1, HSD17B7, CYP11B2 | ERN1 1752/4885NR3C1 161/4885ALDH1A1 1770/4885 |
| US-20040048858-A1 | Chalcone derivatives and their use to treat diseases | CYP46A1, CYP11B1, HSD17B7 | ERN1 1076/4885NR3C1 99/4885ALDH1A1 792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.